Gene therapy, as an emerging therapy method that focuses on the utilization of the therapeutic delivery of nucleic acids into a patient’s cells as a drug to treat disease.
The potential and feasibility of gene therapy have been proven by many experiences and real cases. BIB, as a worldwide CDMO company, we’re devoted to providing advanced and high qualified gene therapy service to our clients.
Generally, gene therapy can be split into two categories, one is in vivo, one is ex vivo. Ex vivo, which means cells are modified outside the body and then transplanted back in again. First, we need to extract stem cells. Then during the laboratory cultivation process, the vector virus carrying the gene will fuse with the cells. The cells grow in the laboratory and are then returned to the patient by injection. In contrast, in vivo means interior. In this way, the gene is transferred to cells inside the patient’s body via injection.
Both categories are based on Adeno-associated viruses (AAV) and its related technology and production. BIB has a highly experienced technical team and well-versed project management service, which will ensure your satisfaction after your project. For our AAV-focused technology, we mastered plasmid generation, plasmid scale-up, gene editing, AAV host cell screening and AAV Titer optimization, which can ensure our AAV design quality. What’s more, as your one-stop-shop, BIB also provides expression and purification services and analytical services.
